Articles
8 June 2009
Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
https://doi.org/10.4081/hmr.v2i7.421

What will be the future after R-CHOP in patient with DLBCL?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
169
Views
234
Downloads

Authors

B Coiffier
support@pagepress.org
R-CHOP (combination of rituximab plus standard CHOP regimen) has become the standard for treating patients with diffuse large B-cell lymphoma (DLBCL). This combination of 8 cycles of chemo-immunotherapy every 3 weeks was demonstrated as superior to CHOP alone in several studies in different settings. It allows increasing the CR rate, decreasing the relapse rate, prolonging event-free survival, progression-free survival, disease-free survival, and overall survival. This is true in young and elderly patients, in patients with low- or high-risk lymphoma. However, several questions remain for improving on these results.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



What will be the future after R-CHOP in patient with DLBCL?. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.421